Search
CELL BANK Website

Back Back
Cell No. : Cell Name
RCB2231 : HS-SY-II  update : 2022/01/25
CommentHuman cell line derived from synovial sarcoma. Application consideration
Comment from the depositor
Terms and conditionsThere is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC.
Remarks
Order Form Order Form(C-0005.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
Basic information Depositor Sonobe, Hiroshi
Originator Sonobe, Hiroshi
Year of deposit 2002
Animal human < Mammals
Genus Homo
Species sapiens
Tissue lung, pleural effusion
Disease name synovial sarcoma
Classification cancer
Lifespan infinite
Morphology other
Cellosaurus(Expasy) CVCL_8719
deposit info
lot info
Medium Medium List
Culture type Adherent cells
Medium and additives DMEM (low glucose) + 10% FBS
Antibiotics Free
Passage method 0.25% Trypsin
Culture information Passage ratio 1 : 8 split
SC frequency Subculture : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma (-)
Isozyme LD, NP
STR(human) OK
Images
deposit info
lot info
Reference information Reference 6
User's Publication 19


To topTop
Reference
15489  Yokoo S, Fujiwara T, Yoshida A, Uotani K, Morita T, Kiyono M, Hasei J, Nakata E, Kunisada T, Iwata S, Yonemoto T, Ueda K, Ozaki T.  Liquid Biopsy Targeting Monocarboxylate Transporter 1 on the Surface Membrane of Tumor-Derived Extracellular Vesicles from Synovial Sarcoma  Cancers (Basel)  2021  13(8):1823  PubMed ID: 33920416   DOI: 10.3390/cancers13081823
16680  Kusabe Y, Kawashima H, Ogose A, Sasaki T, Ariizumi T, Hotta T, Endo N.  Effect of temozolomide on the viability of musculoskeletal sarcoma cells  Oncol Lett  2015  10(4):2511-2518  PubMed ID: 26622881   DOI: 10.3892/ol.2015.3506
16758  Michels S, Trautmann M, Sievers E, Kindler D, Huss S, Renner M, Friedrichs N, Kirfel J, Steiner S, Endl E, Wurst P, Heukamp L, Penzel R, Larsson O, Kawai A, Tanaka S, Sonobe H, Schirmacher P, Mechtersheimer G, Wardelmann E, Büttner R, Hartmann W.  SRC signaling is crucial in the growth of synovial sarcoma cells  Cancer Res  2013  73(8):2518-28  PubMed ID: 23580575   DOI: 10.1158/0008-5472.CAN-12-3023
9008  Hill BB, Zweng TN, Maley RH, Charash WE, Toursarkissian B, Kearney PA.  Growth suppression and apoptosis induction in synovial sarcoma cell lines by a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ)  Cancer Lett  2008  272(2):336-44  PubMed ID: 18760530   DOI: 10.1016/j.canlet.2008.07.021
3904  Ono H, Yoshikawa H, Ueda T, Yamamura H, Kudawara I, Manou M, Ishiguro S, Funai H, Koyanagi Y, Araki N, Hashimoto N, Sonobe H, Tatsuta M, Takahashi K.  Expression of smooth muscle calponin in synovial sarcoma  Sarcoma  1999  3(2):107-13  PubMed ID: 18521272   DOI: 10.1080/13577149977730
3502  Sonobe H, Manabe Y, Furihata M, Iwata J, Oka T, Ohtsuki Y, Mizobuchi H, Yamamoto H, Kumano O, Abe S.  Establishment and characterization of a new human synovial sarcoma cell line, HS-SY-II  Lab Invest.  1992  67:498-505  PubMed ID: 1331610  

To topTop
User's Publication
20170  Yamada H, Takahashi M, Watanuki M, Watanabe M, Hiraide S, Saijo K, Komine K, Ishioka C.  lncRNA HAR1B has potential to be a predictive marker for pazopanib therapy in patients with sarcoma.  Oncol Lett  2021  21(6):455  PubMed ID: 33907565   DOI: 10.3892/ol.2021.12716
14894  Jerby-Arnon L, Neftel C, Shore ME, Weisman HR, Mathewson ND, McBride MJ, Haas B, Izar B, Volorio A, Boulay G, Cironi L, Richman AR, Broye LC, Gurski JM, Luo CC, Mylvaganam R, Nguyen L, Mei S, Melms JC, Georgescu C, Cohen O, Buendia-Buendia JE, Segerstolpe A, Sud M, Cuoco MS, Labes D, Gritsch S, Zollinger DR, Ortogero N, Beechem JM, Petur Nielsen G, Chebib I, Nguyen-Ngoc T, Montemurro M, Cote GM, Choy E, Letovanec I, Cherix S, Wagle N, Sorger PK, Haynes AB, Mullen JT, Stamenkovic I, Rivera MN, Kadoch C, Wucherpfennig KW, Rozenblatt-Rosen O, Suvà ML, Riggi N, Regev A.  Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcoma  Nat Med  2021  ;27(2):289-300  PubMed ID: 33495604   DOI: 10.1038/s41591-020-01212-6
15529  Boulay G, Cironi L, Garcia SP, Rengarajan S, Xing YH, Lee L, Awad ME, Naigles B, Iyer S, Broye LC, Keskin T, Cauderay A, Fusco C, Letovanec I, Chebib I, Nielsen PG, Tercier S, Cherix S, Nguyen-Ngoc T, Cote G, Choy E, Provero P, Suvà ML, Rivera MN, Stamenkovic I, Riggi N.  The chromatin landscape of primary synovial sarcoma organoids is linked to specific epigenetic mechanisms and dependencies  Life Sci Alliance  2021  4(2):e202000808    DOI: 10.26508/lsa.202000808
16177  Fairchild CK Jr, Floros KV, Jacob S, Coon CM, Puchalapalli M, Hu B, Harada H, Dozmorov MG, Koblinski JE, Smith SC, Domson G, Leverson JD, Souers AJ, Takebe N, Ebi H, Faber AC, Boikos SA.  Unmasking BCL-2 Addiction in Synovial Sarcoma by Overcoming Low NOXA  Cancers (Basel)  2021  13(10):2310  PubMed ID: 34065859   DOI: 10.3390/cancers13102310
13035  Sekita T, Yamada T, Kobayashi E, Yoshida A, Hirozane T, Kawai A, Uno Y, Moriyama H, Sawa M, Nagakawa Y, Tsuchida A, Matsumoto M, Nakamura M, Nakayama R, Masuda M.  Feasibility of Targeting Traf2-and-Nck-Interacting Kinase in Synovial Sarcoma.  Cancers (Basel)  2020    PubMed ID: 32429395   DOI: 10.3390/cancers12051258
14524  Abe K, Yamamoto N, Domoto T, Bolidong D, Hayashi K, Takeuchi A, Miwa S, Igarashi K, Inatani H, Aoki Y, Higuchi T, Taniguchi Y, Yonezawa H, Araki Y, Aiba H, Minamoto T, Tsuchiya H.  Glycogen synthase kinase 3β as a potential therapeutic target in synovial sarcoma and fibrosarcoma  Cancer Sci  2020  111(2):429-440  PubMed ID: 31808966   DOI: 10.1111/cas.14271
14832  Saito S, Kitamura-Muramatsu Y, Komine F, Polat M, Takeshima SN, Takei M, Aida Y.  Absence of bovine leukemia virus proviral DNA in Japanese human blood cell lines and human cancer cell lines  Arch Virol  2020  165(1):207-214  PubMed ID: 31776677   DOI: 10.1007/s00705-019-04474-9
14603  Michel BC, D'Avino AR, Cassel SH, Mashtalir N, McKenzie ZM, McBride MJ, Valencia AM, Zhou Q, Bocker M, Soares LMM, Pan J, Remillard DI, Lareau CA, Zullow HJ, Fortoul N, Gray NS, Bradner JE, Chan HM, Kadoch C.  A non-canonical SWI/SNF complex is a synthetic lethal target in cancers driven by BAF complex perturbation  Nat Cell Biol  2018  20(12):1410-1420  PubMed ID: 30397315   DOI: 10.1038/s41556-018-0221-1
10309  Yamada S, Imura Y, Nakai T, Nakai S, Yasuda N, Kaneko K, Outani H, Takenaka S, Hamada K, Myoui A, Araki N, Ueda T, Itoh K, Yoshikawa H, Naka N.  Therapeutic potential of TAS-115 via c-MET and PDGFRα signal inhibition for synovial sarcoma.  BMC Cancer  2017  17:334  PubMed ID: 28511645   DOI: 10.1186/s12885-017-3324-3
14617  Jones SE, Fleuren EDG, Frankum J, Konde A, Williamson CT, Krastev DB, Pemberton HN, Campbell J, Gulati A, Elliott R, Menon M, Selfe JL, Brough R, Pettitt SJ, Niedzwiedz W, van der Graaf WTA, Shipley J, Ashworth A, Lord CJ.  ATR Is a Therapeutic Target in Synovial Sarcoma  Cancer Res  2017  77(24):7014-7026  PubMed ID: 29038346   DOI: 10.1158/0008-5472.CAN-17-2056
9547  Yasui H, Imura Y, Outani H, Hamada K, Nakai T, Yamada S, Takenaka S, Sasagawa S, Araki N, Itoh K, Myoui A, Yoshikawa H, Naka N.  Trabectedin is a promising antitumour agent for synovial sarcoma.  J Chemother  2016  28:417-24  PubMed ID: 27077926   DOI: 10.1080/1120009X.2015.1133013
9557  Sakurai T, Yoshiga D, Ariyoshi W, Okinaga T, Kiyomiya H, Furuta J, Yoshioka I, Tominaga K, Nishihara T.  Essential role of mitogen-activated protein kinases in IL-17A-induced MMP-3 expression in human synovial sarcoma cells.  BMC Res Notes  2016  9:68  PubMed ID: 26850593   DOI: 10.1186/s13104-016-1892-y
9653  Kawano S, Asano M, Adachi Y, Matsui J.  Antimitotic and Non-mitotic Effects of Eribulin Mesilate in Soft Tissue Sarcoma.  Anticancer Res.  2016  36:1553-61  PubMed ID: 27069131  
9751  Kawano S, Grassian AR, Tsuda M, Knutson SK, Warholic NM, Kuznetsov G, Xu S, Xiao Y, Pollock RM, Smith JS, Kuntz KK, Ribich S, Minoshima Y, Matsui J, Copeland RA, Tanaka S, Keilhack H.  Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma.  PLoS ONE  2016  11:e0158888  PubMed ID: 27391784   DOI: 10.1371/journal.pone.0158888
10919    Antitumor activities of BIBF 1120, BI 860585, and BI 836845 in preclinical models of sarcoma  Integr Mol Med  2016  3: 755-760    DOI: 10.15761/IMM.1000239
14025  Imura Y, Nakai T, Yamada S, Outani H, Takenaka S, Hamada K, Araki N, Itoh K, Yoshikawa H, Naka N.  Functional and therapeutic relevance of hepatocyte growth factor/c-MET signaling in synovial sarcoma  Cancer Sci  2016  107(12):1867-1876  PubMed ID: 27779808   DOI: 10.1111/cas.13092
7359  Mikami T, Kurose A, Javed F, Takeda Y.  Detection of Rare Variant of SS18-SSX1 Fusion Gene and Mutations of Important Cancer-Related Genes in Synovial Sarcoma of the Lip: Gene Analyses of a Case and Literature Review.  J. Oral Maxillofac. Surg.  2015  73:1505-15  PubMed ID: 25959879   DOI: 10.1016/j.joms.2015.02.010
13716    Metastatic potential is determined early in synovial sarcoma development and reflected by tumor molecular features  Int J Biochem Cell Biol  2014  53:505-13  PubMed ID: 24842110   DOI: 10.1016/j.biocel.2014.05.006
8002  Hisaoka M, Matsuyama A, Nagao Y, Luan L, Kuroda T, Akiyama H, Kondo S, Hashimoto H.  Identification of altered MicroRNA expression patterns in synovial sarcoma.  Genes Chromosomes Cancer  2011  50:137-45  PubMed ID: 21213367   DOI: 10.1002/gcc.20837



Back Back Return Top Page